23 results about "Paroxysmal AF" patented technology

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

Methods and compositions are provided for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitor in an amount effective to inhibit MASP-3-dependent complement activation. Methods and compositions for increasing red blood cell survival in a subject suffering from paroxysmal nocturnal hemoglobinuria are provided by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitor and / or a MASP-3 inhibitor, the amount of the inhibitor being effective to increase red blood cell survival. A MASP-2 inhibitor and a MASP-1 inhibitor, a MASP-2 inhibitor and a MASP-3 inhibitor, a MASP-3 inhibitor and a MASP-1 inhibitor, or a MASP-1 inhibitor, a MASP-2 inhibitor and a MASP-3 inhibitor may be administered to the subject.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.

An electrocardiogram analysis apparatus includes a machine learning part that has a machine learning model realized by machine learning that uses training electrocardiogram data of a patient with paroxysmal arrhythmia during a non-paroxysmal period during which no episode of paroxysmal arrhythmia occurs; an input processing part that inputs electrocardiogram data of a person to be analyzed, which is a subject of analysis, into the machine learning model; and an output control part that outputs, to an information terminal, abnormality information which is to be output from the machine learning model and is about whether the person to be analyzed has paroxysmal arrhythmia.

The present disclosure relates to compositions and methods, including prodrugs of (S)-sec-butyl 2-(3-(4-(2- (diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl) acetate that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, ventricular arrhythmias, or ventricular fibrillation.

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

Methods of treating paroxysmal nocturnal hemoglobinuria using MASP-3 serine protease inhibitors are provided. In some embodiments, the MASP-3 serine protease inhibitors are anti-MASP-3 antibodies. Also provided are uses of MASP-3 serine protease inhibitors in treatment of paroxysmal nocturnal hemoglobinuria, and for manufacture of a medicament for treatment of paroxysmal nocturnal hemoglobinuria.

Provided are systems and methods that may be employed to detect the presence or absence of paroxysmal nocturnal hemoglobinuria (PNH) in a subject that includes a leukocyte including GPI-anchors the leukocyte incubated with one or more blocking agents each independently specific to one or more GPI-anchored proteins, the leukocyte further incubated with a pro-aerolysin or derivative thereof, and optionally a second leukocyte including GPI-anchors not incubated with one or more of the blocking agents. The systems may be used as a positive control in assays detecting the presence or absence of PNH.

Provided are systems and methods that may be employed to detect the presence or absence of paroxysmal nocturnal hemoglobinuria (PNH) in a subject that includes a leukocyte including GPI-anchors the leukocyte incubated with one or more blocking agents each independently specific to one or more GPI-anchored proteins, the leukocyte further incubated with a pro-aerolysin or derivative thereof, and optionally a second leukocyte including GPI-anchors not incubated with one or more of the blocking agents. The systems may be used as a positive control in assays detecting the presence or absence of PNH.

The present disclosure relates to stable aqueous solutions comprising high concentrations of an anti-C5 antibody (e.g., ravulizumab) and methods of making the solutions. The present disclosure also provides methods of using the solutions to treat or prevent complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Therapeutic kits containing one or more of the solutions, and means for administering the solutions to a patient in need of such treatment, are also contemplated.

Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.

For paroxysmal or persistent AFib patients, if its untreated AFib level exceeds a threshold level of AFib, treatment is eligible with a drug (e.g., Bronidalon) capable of controlling the patient's heart rhythm. A qualified patient is subjected to drug treatment while monitoring its heart rate using a wearable device. If it is considered that the administered dose of medicament is invalid, adjusting the dose until an effective dose is determined for the patient; if the patient is confirmed to be non-reactive to the drug, the treatment is withdrawn.

Disclosed are methods for cardioversion using bundanolol or a pharmaceutical composition comprising bundanolol for cardioversion of patients with paroxysmal or persistent AFib.

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

The present disclosure relates to the use of a Factor B inhibitor in the treatment of paroxysmal nocturnal hemoglobinuria. Specifically, the present disclosure relates to the use of the Factor B inhibitor or a pharmaceutically acceptable salt thereof in the preparation of a formulation for treating paroxysmal nocturnal hemoglobinuria (PNH) previously using a C5 complement inhibitor, wherein the Factor B inhibitor is represented by formula (I), (II) or (III).

In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

Patients with paroxysmal or persistent atrial fibrillation whose untreated atrial fibrillation exceeds the threshold level are eligible for treatment with a drug that can control the patient's heart rhythm (e.g., budiodarone). Eligible patients are treated with the drug while their heart rate is monitored using a wearable device, and if a given drug dose is deemed ineffective, the dose is adjusted until an effective dose is determined for the patient or the patient is deemed unresponsive to the drug and is discontinued from treatment.

The present invention provides a method for extracting abnormal waveforms from a portable electrocardiogram measurement device, the method extracting characteristic abnormal waveforms from an electrocardiogram waveform measured through the portable electrocardiogram measurement device and converting same into data, thereby being used, on the basis thereof, for the determination and diagnosis of arrhythmias including paroxysmal atrial fibrillation and, furthermore, minimizing vibration and noise during electrocardiogram measurement so that accurate electrocardiogram measurement can be promoted. According to the present invention, the method for extracting abnormal waveforms from a portable electrocardiogram measurement device, which comprises a sensor unit in contact with the human body, a control unit for receiving and processing signals detected by the sensor unit, and a display unit for displaying electrocardiogram information, is provided, the method comprising: an electrocardiogram signal acquisition step of acquiring electrode signals measured by the sensor unit; a normalizing signal generation step of detecting a plurality of R signals from the acquired electrode signals and generating normalizing signals in which periods of the R signals are regularly rearranged; an abnormal waveform extraction step of extracting R signals that are beyond a preset reference range among the R signals generated in the normalizing generation step; and an abnormal waveform visualization step of visualizing and providing signals of the extracted abnormal waveforms as an electrocardiogram graph.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, pemphigus, e.g., pemphigus vulgaris (PV) and pemphigus foliaceus (PF), and C3 glomerulopathy.